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An isochromosome 17 results in a loss of the short arm 
(17p) and duplication of the long arm (17q) leading to a 
single copy of 17p and three copies of 17q. 
An i(17q), usually observed in a complex karyotype, 
has been reported in solid tumors and in various types 
of hematological diseases: acute myeloid leukemias 
and chronic myeloid leukemias, myelodysplastic 
syndromes and myeloproliferative neoplasms, acute 
lymphoid leukemias and chronic lymphoid leukemias, 
and Hodgkin and non-Hodgkin lymphomas. 
In chronic myeloid leukemia, i(17q) is a frequent ad 
well known secondary anomaly, either solely in 10% of 
cases, or with other additional anomalies , in at le st 
another 10% of cases, in particular with +8.  
It is believed that i(17q) as a sole abnormality is a 
distinctive clinicopathological entity with a high risk to 
a leukemic progression; a subset may present as de 
novo AML. These neoplasms have distinctive 
morphologic features, including multilineage dysplaia 
and concurrent myeloproliferative features. 
Isochromosome 17q usually occurs at time of blast 
transformation and heralds an aggressive clinical 
course. In the 2008 World Health Organization (WHO) 
classification system, myeloid neoplasms with 
isochromosome 17q are only briefly mentioned within 
the MDS/MPN category. 
 
 




Phenotype/cell stem origin 
Previous studies on isolated i(17q) have suggested this 
aberration was associated with chronic myeloid 
abnormalities with a high rate of progression to AML; 
a new clinico-pathological entity in which i(17q) is the 
sole abnormality has been reported in a mixed 
myeloproliferative disorder / myelodysplastic 
syndrome with an aggressive course. 
Etiology 
i(17q) as sole cytogenetic aberration represents only
1% of cases in myeloid malignancies. 
Clinics 
Isolated isochromosome 17q cases can be divided into 
2 distinct subgroups based on the presentation: de ovo
AML and MDS/MPN.  
All de novo AML fit into the WHO classification of 
AML with myelodysplasia-related changes (with the 
exception of 1 mixed phenotype acute leukemia), and 
showed features of both myelodysplasia (pseudo-
Pelger-Huet-like neutrophils, micromegakaryocytes) 
and myeloproliferation (splenomegaly, 
hypercellularity, reticulin fibrosis, osteosclerosis). 
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i(17q) G- banding (left) - Courtesy Jean-Luc Lai (top) and Diane H. Norback, Eric B. Johnson, and Sara Morrison-Delap, UW Cytogenetic 
Services (middle and bottom); and R- banding (right) - top: Editor, bottom: Courtesy Jacques Boyer
 
Cytology 
A severe hyposegmentation of neutrophil nuclei 
(pseudo-Pelger Huet neutrophils (PHH)) and a 
prominence of the monocyte/macrophage lineage has 
been noted; other studies have identified an associati n 
between hyposegmented neutrophils and loss of 17p 
(called 17p- syndrome), always included in complex 
karyotypes; the i(17q) appeared to be a part of the 
malignant clone as demonstrated in cases available for 
a FISH analysis: all myeloid cell lines observed 
contained the abnormal i(17q), whereas none of the 
lymphocytes were affected. Morphologically, all 
showed myelodysplastic and myeloproliferative 
features, including pseudo-Pelger-Huet-like 
neutrophils, micromegakaryocytic hyperplasia, 
hypercellularity, fibrosis, and osteosclerosis. 
Pathology 
We recommend that for cases with morphologic 
features suggestive of isochromosome 17q, such as 
pseudo-Pelger-Huet-like neutrophils or 
micromegakaryocytes, a complete workup with 
ancillary studies should be performed to explore 
features of both myelodysplasia and myeloproliferation 
to better classify the disease process, including stain  
for reticulum and collagen, immunostains using CD61 
to reveal micromegakaryocytes, CD34 and CD117 to 
quantify the blasts on the core biopsy, iron stain to 
assess storage iron and ring sideroblasts, butyrate 
esterase stain to quantify monocytes, and 
myeloperoxidase stain to determine percentage and 
lineage of the blasts, as well as flow cytometry 
immunophenotyping of the blasts, cytogenetic 
analysis for the detection of isochromosome 17q, and 
mutational studies of common molecular markers seen 
in myeloid neoplasms.  
Review of the peripheral blood smear and clinical 
records with special attention to the presence of 
splenomegaly may also be helpful. 
Evolution 
Mutational analyses showed rare mutations in NRAS (3 
of 10), FLT3 (2 of 16), and JAK2 (1 of 18), and no 
mutations in NPM1 (0 of 15), KIT (0 of 4), and 
CEBPA (0 of 4).  
Mutations of JAK2, FLT3, RAS, NPM1, KIT, and 
CEBPA are rare and appear to not play a critical role in 
the pathogenesis of isochromosome 17q leukemia. 
Prognosis 
Log-rank test, and univariate and multivariate Cox 
proportional hazards regression analyses to evaluate 
prognostic values of patients' characteristics, including 
age >65 years, sex, leukocytosis, anemia, 
thrombocytopenia, absolute monocytosis, elevated 
lactate dehydrogenase, elevated β2-microglobulin, 
splenomegaly, megakaryocytic hyperplasia, 
dysgranulocytes, dyserythrocytes, dysmegakaryocytes, 
increased blasts, bone thickness, cytogenetic evidence 
of clonal evolution, mutations of JAK2 V617F, FLT3, 
or NRAS, and stem cell transplantation. In the 
univariate analysis, log-rank test suggested that OS was 
significantly associated with stem cell transplantation 
and absolute monocytosis.  
Patients with stem cell transplantation had a longer 
survival (P = 0,042), and absolute monocytosis was 
associated with a shorter survival (P = 0,016). 
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Kaplan-Meier curve of overall survival (OS) of patients with myeloid neoplasms and isolated isochromosome 17q is shown. The median 
OS of de novo acute myeloid leukemia (AML) and of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) was 14,5 months and 




DNA sequencing of exons 2-11 of the TP53 gene, 
representing the entire coding region. No mutation was 
detected in all 14 cases assessed. None of the 13 cases 
tested had bcr-abl1 fusion transcripts. It has been 
proposed that TP53 deletion/mutation might be 
responsible for the unique clinicopathologic features of 
myeloid neoplasms associated with isochromosome 
17q. We can conclude that DNA sequencing showed no 
mutation in the involved TP53 allele. 
Genes involved and proteins 
Note 
The underlying molecular defect that produces the 
isolated i(17q) is unknown: breakage of the proximal p 
arm (17p11.2) with rejoining of both centromere-
containing chromatids and subsequent inactivation of 
one centromere; breakpoints could involve important 
genetic material whose disruption could result in 
oncogene or tumor suppression gene deregulation.  
In understanding the specific i(17q) phenotype, loss f 
genes localized on 17p were suggested as p53 
(17p13.1); a direct correlation between p53 loss and
PHH neutrophils was found in a series of MDS and 
ANLL with 17p- syndrome. However, Fioretos et al. 
assessed TP53 mutations in 5 Philadelphia negative 
myeloid neoplasms with isolated isochromosome.  
17q by sequencing, and found no mutation in all 5 
cases. Similarly, none of the 14 cases assessed in 
another series of patients demonstrated TP53 mutation. 
These results suggest that there is no association 
between isochromosome 17q and TP53 mutations, and 
that another oncogene(s) at 17q and/or tumor 
suppressor gene(s) at 17p may play an important role in 
the pathogenesis of isochromosome 17q-associated 
myeloid neoplasms. The presence of a moderate 
apoptotic rate also suggests that the cytogenetically 
uninvolved TP53 allele is functional. 
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